Pharma & Biotech UBS says market has turned too pessimistic on AI as themes climb back up rankings By Ian Lyall 15/07
Medical technology & services Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies By Emily Jarvie 15/07
Medical technology & services Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance By Emily Jarvie 15/07
Pharma & Biotech CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held By Ian Lyall 15/07
Pharma & Biotech AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill By Ian Lyall 14/07
Pharma & Biotech Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress By Ian Lyall 14/07
Pharma & Biotech Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial By Ian Lyall 13/07
Pharma & Biotech UBS keeps GSK at 'neutral' with focus on chief executive's strategy update By Ian Lyall 13/07
Pharma & Biotech UBS stays positive on AstraZeneca ahead of second-quarter results By Ian Lyall 13/07
Pharma & Biotech Oxford Nanopore shares slide 16% after first-half sales miss expectations By Ian Lyall 13/07
Pharma & Biotech Incanthera aims to streamline following énielle deal, makes management changes By Jamie Ashcroft 13/07
Pharma & Biotech Genflow Biosciences dog trial continues to show longevity improvements By Jamie Ashcroft 13/07
